# Expanded Access for Repotrectinib

> **NCT05926232** · — · AVAILABLE · sponsor: **Bristol-Myers Squibb**

## Conditions studied

_None listed._

## Interventions

- **DRUG:** Repotrectinib

## Key facts

- **NCT ID:** NCT05926232
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05926232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05926232, "Expanded Access for Repotrectinib". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05926232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*